[1] 新注册分类的皮肤外用仿制药的技术评价要求(征求意见稿)[EB/OL]. [2020-10-11]. http://www.cde.org.cn/news.do?method=largeInfo&id=9f58eb9a8abeed59
Technical Evaluation Requirements for The New Registration Classification of Generic Drugs for External Use on Skin(Draft for Solicitation of Comments) [EB/OL]. [2020-10-11]. http://www.cde.org.cn/news.do?method=largeInfo&id=9f58eb9a8abeed59
[2] 皮肤外用化学仿制药研究技术指导原则(试行)[EB/OL]. [2021-06-16]. http://www.cde.org.cn/search.do?method=search
TitleGuiding Principles of Research on Generic Drugs for External Use of Skin Chemicals(Trial) [EB/OL]. [2021-06-16]. http://www.cde.org.cn/search.do?method=searchTitle
[3] 田洁. 皮肤外用半固体制剂体外透皮吸收对比试验常见问题分析[J].中国新药杂志, 2016, 25(18):2113
TIAN J. Main problems and analysis of the in vitro transdermal absorption comparative test of skin’s external semisolid preparations[J].Chin New Drugs J, 2016, 25(18):2113
[4] SUPAC-SS:Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes:Chemistry, Manufacturing and Controls; In vitro Release Testing and In vivo Bioequivalence Documentation [EB/OL]. [2020-05-21]. https://www.fda.gov/media/71141/download
[5] GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2018-2022 (GDUFA Ⅱ Commitment Letter) [EB/OL]. [2020-12-31]. https://www.fda.gov/media/101052/download
[6] Product-Specific Guidances for Generic Drug Development[EB/OL]. [2021-10-22]. https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm?event=Home.Search#letterSearchBar
[7] 临床试验登记与信息公示平台[EB/OL]. [2020-11-29]. http://www.chinadrugtrials.org.cn
Clinical Trial Registration and Information Disclosure Platform[EB/OL]. [2020-11-29]. http://www.chinadrugtrials.org.cn
[8] 以药动学参数为终点评价指标的化学药物仿制药人体生物等效性研究技术指导原则[EB/OL]. [2020-10-24]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html
Technical Guidelines for Research on Human Bioequivalence of Generic Chemical Drug with Pharmacokinetic Parameters as The Endpoint Evaluation Index[EB/OL]. [2020-10-24]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html
[9] 化学仿制药透皮贴剂药学研究技术指导原则[EB/OL]. [2020-10-24]. http://www.cnpharm.com/c/2020-07-24/744541.shtml
Guiding Principles for Pharmaceutical Research of Transdermal Patches of Chemical Generic Drugs[EB/OL]. [2020-10-24]. http://www.cnpharm.com/c/2020-07-24/744541.shtml
[10] Topical Dermatologic Corticosteroids:in vivo Bioequivalence[EB/OL]. [2020-10-24]. https://www.fda.gov/media/70931/download
[11] SIEWERT M, DRESSMAN JK, BROWN C, et al. FIP/AAPS Guidelines to dissolution/in vitro release testing of novel/special dosage forms[J/OL].AAPS Pharm Sci Tech, 2003, 4(1):Article 7. https://link.springer.com/content/pdf/10.1208%2Fpt040107.pdf
[12] Residual Drug in Transdermal and Related Drug Delivery Systems[EB/OL]. [2020-10-24]. https://www.fda.gov/media/79401/download
[13] Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA[EB/OL]. [2021-09-10]. https://www.fda.gov/media/87219/download
[14] Draft Guidance on Acyclovir[EB/OL]. [2020-10-24]. https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acyclovir_topical%20cream_RLD%2021478_RV12-16.pdf
[15] ANDA Submissions-Refuse-to-Receive Standards Guidance for Industry [EB/OL]. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), [2020-10-24]. https://www.fda.gov/media/86660/download
[16] Assessing Adhesion with Transdermal Delivery Systems and Topical Patches for ANDAs[EB/OL]. [2020-10-24]. https://www.fda.gov/media/98634/download
[17] Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs[EB/OL]. [2020-10-24]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas
[18] FDA:Transdermal and Topical Delivery Systems-Product Development and Quality Considerations[EB/OL]. [2020-10-24]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations
[19] Contact Dermatitis from Topical Drug Products for Cutaneous Application:Human Safety Assessment Guidance for Industry[EB/OL]. [2020-10-24]. https://www.fda.gov/media/135888/download
[20] European Medicines Agency. Guideline, Clinical Investigation of Corticosteroids Intended for Use on The Skin[EB/OL]. [2020-10-24]. https://www.ema.europa.eu/en/documents/scientific-guideline/clinical-investigation-corticosteroids-intended-use-skin_en.pdf
[21] European Medicines Agency. Guideline, Clinical Requirements for Locally Applied, Locally Acting Products, Containing Known Constituents[EB/OL]. [2020-10-24]. https://www.ema.europa.eu/en/documents/scientificguideline/note-guidance-clinical-requirements-locallyappliedlocally-acting-products-containing-known_en.pdf
[22] Guideline on Quality of Transdermal Patches[EB/OL]. [2020-10-24]. https://www.ema.europa.eu/en/quality-transdermal-patches
[23] European Medicines Agency. Draft Guideline on Quality and Equivalence of Topical Products[EB/OL]. [2020-10-24]. https://www.ema.europa.eu/en/quality-equivalence-topical-products
[24] Test Guideline 427:Skin Absorption:In vivo Method[EB/OL]. [2020-10-24]. https://www.oecd-ilibrary.org/docserver/9789264071063-en.pdf?expires=1609729912&id=id&accname=guest&checksum=A52D2 E9267064125A47B20C89898F56E
[25] Guidance Document for The Conduct of Skin Absorption Studies[EB/OL]. [2020-10-24]. https://www.oecd-ilibrary.org/docserver/9789264078796-en.pdf?expires=1610349102&id=id&accname=guest&checksum=81E443BE5E6CB90BB5A0F493F66473CD
[26] Test Guideline 428:Skin Absorption: In Vitro Method[EB/OL]. [2020-10-24]. https://link.springer.com/chapter/10.1007/978-1-4939-1289-6_22
[27] 多来源(仿制)药品:建立可互换性注册要求的指导原则[S]. WHO药品标准专家委员会第40次技术报告. 世界卫生组织:日内瓦;2006, 附录7(WHO技术报告系列,第937号)
Multi-Source(Generic) Drugs: Guidelines for Establishing Interchangeability Registration Requirements[S]. The 40th Technical Report of The WHO Expert Committee on Pharmaceutical Standards. WHO:Geneva;2006, Appendix 7(WHO Technical Report Series, No.937)
[28] Minister of Health, Labour and Food Safety Bureau. NIHS. Guideline for Bioequivalence Studies of Generic Products for Topical Use[EB/OL]. [2020-10-24]. http://www.nihs.go.jp/drug/be-guide(e)/Topical_BE-E.pdf
[29] Inister of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau. NIHS. Guideline for bioequivalence studies of generic products[EB/OL]. [2020-10-24]. http://ww.nihs.go.jp/drug/be-guide(e)/Generic/GLE_120229BE.pdf
[30] 中华人民共和国药典2020版. 四部[S]. 2020:11
ChP 2020. Vol Ⅳ[S]. 2020:11
[31] USP 42-NF 37[S]. 2018:8311, 600, 78
[32] EP 10.0[S]. 2010:935
[33] CFR 21. 314[EB/OL]. [2020-10-24]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm
[34] CFR 21. 320[EB/OL]. [2020-10-24]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm
[35] CFR 21. 333[EB/OL]. [2020-10-24]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm
[36] CFR 21. 347[EB/OL]. [2020-10-24]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=347&showFR=1
[37] Minister of Health, Labour and Food Safety Bureau. NIHS. Guideline for Bioequivalence Studies of Generic Products for Topical Use[EB/OL]. [2020-10-24]. http://www.nihs.go.jp/drug/be-guide(e)/topical_BE-E.pdf
[38] ALEXANDER H, BROWN S, DANBY S, et al. Research Techniques Made Simple: Transepidermal Water Loss Measurement as a Research Tool[J].J Invest Dermatol, 2018, 138(11):2295
[39] 裴元英. 应用高能药物-聚乙烯吡咯烷酮(PVP)共沉淀体增加药物的膜转运[J].国外医学:药学分册, 1981, 8(2):129
PEI YY. Application of high-energy drug-polyvinylpyrrolidone (PVP) coprecipitate to increase drug membrane transport[J].Foreign Med Sci:Pharm, 1981, 8(2):129
[40] 崔东贤, 李凤龙. 氮酮促进消炎痛透皮吸收的探讨[J].延边医学院学报, 1989(2):94
CUI DX, LI FL. An approach to transdermal absorption of indomethacin promoted by azone[J].J Yanbian Med Coll, 1989(2):94
[41] 杨基森, 林亚平, 张光强, 等. 伤湿止痛橡皮膏中乌头碱体外释放的研究[J].中成药, 1989, 11(11):2
YANG JS, LIN YP, ZHANG GQ, et al. Study on the release of aconitine from Shangshi Zhitong plaster in vitro[J].Chin Tradit Pat Med, 1989, 11(11):2
[42] 李志鸿, 孙鸿安, 王浩,等. 透皮给药研究中体外扩散池的改进[J].中国医药工业杂志, 1995, 26(7):3
LI ZH, SUN HA, WANG H, et al. Preparationof poly(lactic acid)microspheres containing 5-fluorouracil and tests of drug release in vitro/in vivo[J].Chin J Pharm, 1995, 26(7):3
[43] 王松, 容艳芬. 莫匹罗星软膏的体外透皮吸收[J].医药导报, 2018, 37(2):227
WANG S, RONG YF. Percutaneous absorption of mupirocin ointment in vitro[J].Her Med, 2018, 37(2):227
[44] 何爱萍,易红,冯伟红,等. 活血止痛微乳凝胶剂的体外释放和透皮吸收评价[J].中国实验方剂学杂志, 2017, 23(5):17
HE AP, YI H, FENG WH, et al. Evaluation of in vitro release and transdermal absorption of Huoxue Zhitong microemulsion gel[J].Chin J Exp Med Form, 2017, 23(5):17
[45] 李燕,王春艳,任博,等. α-萜品醇脂肪酸酯对格列美脲经皮促渗透作用考察及皮肤刺激性评价[J].中国药师, 2019, 22(6):997
LI Y, WANG CY, REN B, et al. Study on the penetration enhancing effect of α-TER fatty acid esters on glimepiride and evaluation of skin irritation[J].China Pharm, 2019, 22(6):997
[46] BISHARAT L, PERINELLI DR, BERARDI A, et al. Influence of testing parameters on in vitro tramadol release from poloxamer thermogels using the immersion cell method[J].AAPS Pharm Sci Tech, 2017, 18(7):2706
[47] CIOLAN DF, MINEA A, ANDRIE AA, et al. The influence of compendial cells design and experimental setup on the in vitro similarity of ketoconazole topical creams[J].Farmacia, 2015, 63(6):865
[48] PRADEEPKUMAR PS, CHARLES CC. Comparison of diffusion studies of hydrocortisone between the"franz cell"and the new "enhancer cell"[J].Drug Dev Ind Pharm, 1993, 19(13):1573
[49] SINGH I, ABOULENEINHY. Advantages of USP apparatus Ⅳ(flow-through cell apparatus) in dissolution studies[J].J Iran Chem Soc, 2006, 3(3):220
[50] CHATTARAJ SC, KANFER I. ‘The insertion cell’: a novel approach to monitor drug release from semi-solid dosage forms[J].Int J Pharm, 1996, 133(1-2):59
[51] OSMALEK T, MILANOWSKI B, FROELICH A, et al. Novel organogels for topical delivery of naproxen:design, physicochemical characteristics and in vitro drug permeation[J].Pharm Develop Tech, 2016, 11(16):1
[52] 梁佳敏,李楠,徐海蓉,等. 经皮给药系统的体外释放、透皮特性及体内药动学研究进展[J].武警后勤学院学报(医学版), 2013, 22(12):1137
LIANG JM, LI N, XU HR, et al. Pharmacokinetics, release and permeate in vitro on transdermal drug delivery system[J].J Logist Univ CAPF(Med Sci), 2013, 22(12):1137
[53] 古丽巴哈尔·卡吾力,高晓黎. 不同促透剂对黄体酮软膏经皮吸收作用的影响[J].新疆医科大学学报, 2007, 30(4):360
GULIBAHAER KWL, GAO XL. The effect of different transdermal enhancers on percutaneous absorption of progesterone cream[J].J Xinjiang Med Univ, 2007, 30(4):360
[54] 刘红, 吴迪, 谷亦平, 等. 咪喹莫特微乳的制备及体外透皮评价[J].中国医药工业杂志, 2007, 38(7):496
LIU H, WU D, GU YP, et al. Preparation and in vitro transdermal permeation of imiquimod microemulsion[J].Chin J Pharm, 2007, 38(7):496
[55] MOREIRA TS,DE SOUSA VP,PIERRE MB. Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels[J].J Pharm Pharm Sci, 2010, 13(2):286
[56] OBATA Y, OTAKE Y, TAKAYAMA K. Feasibility of transdermal delivery of prochlorperazine[J].Biol Pharm Bull, 2010, 33(8):1454
[57] AMERONGEN I, RONDE H, KLOOSTER N. Physical-chemical characterization of semisolid topical dosage form using a new dissolution system[J].Int J Pharm, 1992, 86(1):9
[58] FLISZAR K A, FORSYTH R J, ZHONG L, et al. Effects of dissolved gases in surfactant dissolution media[J].Dissolut Technol, 2005, 12(3):5
[59] NGSF, ROUSEJ, SANDERSON D, et al. Comparative study of transmembrane diffusion and permeation of ibuprofen across synthetic membranes using franz diffusion cells[J].Pharmaceutics, 2010, 2(2):209
[60] KANFER I, RATH S, PURAZI P, et al. In vitro release testing of semi-solid dosage forms[J].Dissolut Technol, 2017, 24(3):52
[61] GORE AV, LIANG AC, CHIEN YM. Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model[J].J Pharm Sci, 1998, 87(4):441
[62] 柳朋生, 郑家润. 用猪作人透皮实验动物模型的有关资料[J].国外医学 皮肤性病学分册,2001, 27(4):243
LIU PS, ZHENG JR. Relevant information about using pigs as human transdermal experimental animal models[J].Foreign Med Sci Dermatol Venereol, 2001,27(4):243
[63] 周惠惠, 王琦, 梅兴国, 等. 经皮给药系统研究进展[J].湖北科技学院学报(医学版), 2020, 34(1):87
ZHOU HH, WANG Q, MEI XG, et al. Research progress of transdermal drug delivery system[J].J Hubei Univ Sci Technol(Med Sci), 2020, 34(1):87
[64] 肖学成, 张磊, 彭秀菊, 等. 0.1%他克莫司软膏的体外透皮吸收研究[J].北方药学, 2014, 11(3):80
XIAO XC, ZHANG L, PENG XJ, et al. The transdermal research of 0.1% tacrolimus ointment[J].Northern Pharm, 2014, 11(3):80
[65] 朱力阳, 马建, 涂禾, 等. 二黄凝胶贴膏与软膏的体外释放及透皮性能比较[J].华西医学, 2016,31(4):724
ZHU LY, MA J, TU H, et al. Comparison of evalution in vitro between erhuang gal paste and its ointment[J].West China Med J, 2016, 31(4):724
[66] BODE S, BAERT B, VANGELE M, et al. Stability of the OECD model compound benzoic acid in receptor fluids of franz diffusion cells[J].Die Pharmazie, 2007, 62(6):470
[67] 李璐, 周建明, 杨一帆, 等. 复方南星止痛膏活性成分在不同接收介质中的透皮扩散行为比较[J].中国实验方剂学杂志, 2018, 24(3):1
LI L, ZHOU JM, YANG YF, et al. Comparison of the transdermal diffusion behavior of the active ingredients of compound Nanxing analgesic ointment in different receiving media[J].Chin J Exp Tradit Med Form, 2018, 24(3):1
[68] LOBO C. Modeling and comparison of dissolution profiles[J].Eur J Pharm Sci, 2001, 13(2):123
[69] KOIZUMI T, UEDA M, KAKEMI M, et al. Rate of release of medicaments from ointment bases containing drugs in suspension[J].J Pharm Sci, 1975, 23(12):3288
[70] SIEPMANN J, PEPPAS NA. Higuchi equation:derivation, applications, use and misuse[J].Int J Pharm, 2011, 418(1):6
[71] XU X, Al-GHABEISH M, KRISHNAIAH YS, et al. Kinetics of drug release from ointments:role of transient-boundary layer[J].Int J Pharm, 2015, 494(1):31
[72] 侯迪旭, 吴学萍, 李树英. 基于体外释放的半固体制剂透皮吸收及其影响因素探讨[J].中国新药杂志, 2018, 27(15):1807
HOU DX, WU XP, LI SY. Study on transdermal absorption of semisolid preparation based on in vitro release and its influencing factors[J].Chin New Drugs J, 2018, 27(15):1807
[73] XU X, Al-GHABEISH M, KRISHNAIAH YS, et al. Kinetics of drug release from ointments:role of transient-boundary layer[J].Int J Pharm, 2015, 494:31
[74] 李金红, 贺亚静, 贺吉香, 等. 复方利多卡因乳膏体外经皮渗透比较研究[J].中国新药杂志, 2015, 24(13):1541
LI JH, HE YJ, HE JX, et al. comparison of the in vitro percutaneous penetration of compound lidocaine cream[J].Chin New Drugs J, 2015, 24(13):1541
[75] SHAH VP, YACOBI A, FLAVIAN SR, et al. A science based approach to topical drug classification system(TCS)[J].Int J Pharm, 2015, 491(1):21
